Tetsuhiro Harimoto

This paper engineers probiotic bacteria to target granulomas and reduce mycobacterial infection in vitro and in vivo.

This paper presents an implantable material platform that contains engineered bacteria to autonomously deliver therapeutics in a mouse model of prosthetic joint infection.

This study engineers a probiotic bacteria to selectively target pancreatic cancer, improving survival and modulating the tumor microenvironment.

This paper develops a programmable probiotic encapsulation system using synthetic biology to enhance therapeutic delivery in mice by controlling bacterial immunogenicity and survivability.

This study engineers bacteria to sense and grow in response to specific environmental cues, improving targeted colonization in the gastrointestinal tract.

The paper presents a 3-D multicellular model to rapidly screen engineered microbial therapies, identifying effective antitumor candidates and demonstrating scalability across microbial species.